sgi-1776 has been researched along with Carcinogenesis* in 2 studies
2 other study(ies) available for sgi-1776 and Carcinogenesis
Article | Year |
---|---|
Role of oncogene PIM-1 in the development and progression of papillary thyroid carcinoma: Involvement of oxidative stress.
In this study, we aimed to clarify the role of PIM-1 in papillary thyroid carcinoma (PTC) in vitro and investigate the relationship between PIM-1 and redox proteins (NOX4, SOD2, and GPX2) at the tissue and cellular levels. As a PIM-1 inhibitor, SGI-1776 inhibited cell proliferation, colony formation, migration and induced an increase in apoptosis and reactive oxygen species in two PTC cell lines (BCPAP and TPC-1). The expressions of PIM-1, SOD2 and GPX2 were downregulated after siNOX4 exposure. Immunohistochemistry in 120 PTC patients showed that all four proteins exhibited higher expression levels in PTC tissues than in adjacent normal tissues. PIM-1 expression was related to NOX4, SOD2, and GPX2 expressions. The Cancer Genome Atlas database analysis showed the significant correlation between the expression of NOX4 and PIM-1. Our results demonstrated that PIM-1 played an important oncogenic role in PTC carcinogenesis that may be related to oxidative stress. Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Databases, Genetic; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Oncogenes; Oxidative Stress; Proto-Oncogene Proteins c-pim-1; Pyridazines; Reactive Oxygen Species; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tumor Stem Cell Assay | 2021 |
Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is a biologically aggressive cancer. Targeted therapy is in need to tackle challenges in the treatment perspective. A growing body of evidence suggests a promising role of pharmacological inhibition of PIM (proviral integration site for Moloney murine leukaemia virus) kinase in some human haematological and solid cancers. Yet to date, the potential application of PIM inhibitors in HCC is still largely unexplored. In the present study we investigated the pre-clinical efficacy of PIM inhibition as a therapeutic approach in HCC. Effects of PIM inhibitors on cell proliferation, migration, invasion, chemosensitivity, and self-renewal were examined in vitro. The effects of PIM inhibitors on tumour growth and chemoresistance in vivo were studied using xenograft mouse models. Potential downstream molecular mechanisms were elucidated by RNA sequencing (RNA-seq) of tumour tissues harvested from animal models. Our findings demonstrate that PIM inhibitors SGI-1776 and PIM447 reduced HCC proliferation, metastatic potential, and self-renewal in vitro. Results from in vivo experiments supported the role of PIM inhibition in suppressing of tumour growth and increasing chemosensitivity of HCC toward cisplatin and doxorubicin, the two commonly used chemotherapeutic agents in trans-arterial chemoembolisation (TACE) for HCC. RNA-seq analysis revealed downregulation of the MAPK/ERK pathway upon PIM inhibition in HCC cells. In addition, LOXL2 and ICAM1 were identified as potential downstream effectors. Taken together, PIM inhibitors demonstrated remarkable anti-tumourigenic effects in HCC in vitro and in vivo. PIM kinase inhibition is a potential approach to be exploited in formulating adjuvant therapy for HCC patients of different disease stages. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Imidazoles; Liver Neoplasms; Mice; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Xenograft Model Antitumor Assays | 2020 |